Theravance Biopharma Dirección
Dirección controles de criterios 2/4
El CEO de Theravance Biopharma's es Rick Winningham , nombrado en Jun 2014, tiene una permanencia de 9.83 años. compensación anual total es $4.32M, compuesta por 24.3% salario y 75.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.01% de las acciones de la empresa, por valor de $17.80M. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 7.3 años, respectivamente.
Información clave
Rick Winningham
Chief Executive Officer (CEO)
US$4.3m
Compensación total
| Porcentaje del salario del CEO | 24.3% |
| Permanencia del CEO | 9.9yrs |
| Participación del CEO | 4.0% |
| Permanencia media de la dirección | 1.9yrs |
| Promedio de permanencia en la Junta Directiva | 7.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now
May 02
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S
Feb 05Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts
Nov 11Theravance to purchase $95M of ordinary shares
Sep 28Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade
Sep 21Theravance Biopharma announces $250M capital return program
Sep 19Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M
Aug 04Theravance: All-Round Failure
Mar 10Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%
Aug 09Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study
Jun 21Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year
May 09Theravance Biopharma EPS misses by $0.16, misses on revenue
May 04Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why
Apr 21Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)
Mar 13Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value
Mar 08Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$4m | US$1m | -US$55m |
| Sep 30 2023 | n/a | n/a | -US$61m |
| Jun 30 2023 | n/a | n/a | -US$68m |
| Mar 31 2023 | n/a | n/a | -US$75m |
| Dec 31 2022 | US$6m | US$1m | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$136m |
| Jun 30 2022 | n/a | n/a | -US$196m |
| Mar 31 2022 | n/a | n/a | -US$226m |
| Dec 31 2021 | US$4m | US$1m | -US$265m |
| Sep 30 2021 | n/a | n/a | -US$266m |
| Jun 30 2021 | n/a | n/a | -US$264m |
| Mar 31 2021 | n/a | n/a | -US$275m |
| Dec 31 2020 | US$7m | US$1m | -US$295m |
| Sep 30 2020 | n/a | n/a | -US$285m |
| Jun 30 2020 | n/a | n/a | -US$270m |
| Mar 31 2020 | n/a | n/a | -US$247m |
| Dec 31 2019 | US$6m | US$984k | -US$236m |
| Sep 30 2019 | n/a | n/a | -US$221m |
| Jun 30 2019 | n/a | n/a | -US$222m |
| Mar 31 2019 | n/a | n/a | -US$223m |
| Dec 31 2018 | US$3m | US$957k | -US$216m |
| Sep 30 2018 | n/a | n/a | -US$252m |
| Jun 30 2018 | n/a | n/a | -US$260m |
| Mar 31 2018 | n/a | n/a | -US$285m |
| Dec 31 2017 | US$2m | US$933k | -US$285m |
Compensación vs. Mercado: La compensación total de Rick($USD4.32M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.37M).
Compensación vs. Ingresos: La compensación de Rick ha sido consistente con los resultados de la empresa en el último año.
CEO
Rick Winningham (63 yo)
9.9yrs
Permanencia
US$4,318,531
Compensación
Mr. Rick E. Winningham, M.B.A., served as Chairman of Retrotope Inc. since February 2021 until January 2022 . He has been Lead Independent Director and Director of Jazz Pharmaceuticals Public Limited Compa...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 9.9yrs | US$4.32m | 4.01% $ 16.4m | |
| Senior VP & CFO | 1.3yrs | US$1.39m | 0.49% $ 2.0m | |
| VP of IT&I and Chief Information Officer | no data | sin datos | sin datos | |
| Vice President of Corporate Communications & Investor Relations | no data | sin datos | sin datos | |
| Senior VP | 1.9yrs | sin datos | 0.74% $ 3.0m | |
| Chief Business Officer and Senior VP of Commercial & Medical Affairs | 2.4yrs | US$942.81k | 0.72% $ 2.9m | |
| Senior VP & Chief Strategy Officer | 1.7yrs | sin datos | sin datos | |
| SVP of Dev. | no data | sin datos | 0.35% $ 1.4m |
1.9yrs
Permanencia media
53.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de TBPH no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 10.8yrs | US$4.32m | 4.01% $ 16.4m | |
| Independent Director | 9.9yrs | US$205.14k | 0.13% $ 513.9k | |
| Independent Director | 10.6yrs | US$206.68k | 0.22% $ 898.5k | |
| Independent Director | 3.8yrs | US$207.68k | 0.057% $ 234.2k | |
| Lead Independent Director | 9.9yrs | US$211.73k | 0.13% $ 513.9k | |
| Independent Director | 1.1yrs | US$43.10k | sin datos | |
| Independent Director | 8.6yrs | US$195.80k | 0.090% $ 370.4k | |
| Independent Director | 1.3yrs | US$346.47k | 0.014% $ 57.0k | |
| Independent Director | 6.3yrs | US$197.68k | 0.092% $ 376.9k | |
| Independent Director | less than a year | US$168.36k | 0% $ 0 |
7.4yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de TBPH se considera experimentada (7.3 años de antigüedad promedio).